Romosozumab Improves Tissue Thickness–Adjusted Trabecular Bone Score in Women With Osteoporosis and Diabetes - Top-Institutions - MDSpire

Romosozumab Improves Tissue Thickness–Adjusted Trabecular Bone Score in Women With Osteoporosis and Diabetes

  • By

  • Serge Ferrari

  • Donald Betah

  • Robert G Feldman

  • Bente L Langdahl

  • Mary Oates

  • Jen Timoshanko

  • Zhenxun Wang

  • Ruban Dhaliwal

  • January 24, 2025

  • 0 min

Share

Top Institutions in Endocrinology

Brief introduction explaining scope and methodology.

  • #1

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Endocrinology
    • Metabolic Bone Disease
    • Diabetes Research

  • #2

    Massachusetts General Hospital
    Massachusetts General Hospital

    Boston, MA

    Key Differentiators

    • Endocrinology
    • Bone Metabolism
    • Diabetes

  • #3

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Endocrinology
    • Osteoporosis
    • Diabetes Research

  • #4

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, MD

    Key Differentiators

    • Endocrinology
    • Bone Biology
    • Diabetes

  • #5

    University of Michigan
    University of Michigan

    Ann Arbor, MI

    Key Differentiators

    • Endocrinology
    • Metabolic Bone Disease
    • Diabetes

Original Source(s)

Romosozumab Improves Tissue Thickness–Adjusted Trabecular Bone Score in Women With Osteoporosis and Diabetes

  • by Serge Ferrari, Donald Betah, Robert G Feldman, Bente L Langdahl, Mary Oates, Jen Timoshanko, Zhenxun Wang, Ruban Dhaliwal

  • January 24, 2025

Related Content

Retinal Age Model Tied to Disease Risk

Fundus-based tool estimates biologic aging but shows modest gains over prior models

Top 10 States for Physician-Owned Hospitals

These 10 states make it more practical for physicians to participate in hospital ownership by aligning statutory structure, corporate practice of medicine rules, and population trends.

Predicting poor response to anti-osteoporosis therapy: a machine learning model integrating clinical and novel biomarker data